Tony Petrello is a top American corporate executive. He leads a company known as Nabors Industries located in Texas. It is an oil and natural gas exploration and drilling company operating worldwide. There are ongoing works in 25 countries. Tony Petrello has been the face of success in this company. Since he joined, the company has been on a progressive journey, expanding its business activities in all areas.
Before Anthony Petrello joined Nabors in 1991, it was just another company on the list of companies in the energy sector. However, afterward, everything changed. The CEO has helped it move to the top of the list as a top company not only in the country but worldwide. He has assisted the company to make huge acquisitions of rival companies which have assisted it to expand rapidly. The company has also partnered with other players in the industry to make the industry efficiently. Recently, Nabors Industries entered into a partnership with the biggest oil company in the world from Saudi Arabia. Nabors is to offer drilling services to the company which is worth over $10 trillion.
Before he came to this company, Tony Petrello was a lawyer. Yes! A lawyer turned corporate executive. This does not happen often. You have to be very good for any company to trust you with management when you apparently have no experience managing any other company. Petrello was working with Baker & McKenzie, a law firm with offices in New York. It is here where he met the management of Nabors who were his clients. After helping them solve a few issues facing the company, they realized he was actually brilliant and could help them in running the company. That is when they hired him and offered him the position of the Chief Operating Officer.
This was not the only twist in his life. Before Tony Petrello became a lawyer, he was a mathematician. He holds a masters in mathematics from the Yale University. In what was a surprising turn of events while in high school, he was spotted by the University for being exceptionally talented and given the scholarship to study at their campus. He was also to be mentored by the then professor of mathematics at the university known as Serge Lang. Together, they had very good chemistry which saw them work on various mathematical theories. Tony Petrello was not interested in becoming a mathematician. After his masters, he dropped out of the career and started law studies at the Harvard School of law.
The world of science is filled with discoveries that have yet to be tapped. A majority of companies that deal with scientific research have been making enormous strides to make new discoveries in their area of expertise. One such company is Seattle Genetics. The heart of Seattle Genetics research is human antibodies. Seattle Genetics studies, manipulates, and ultimately comes up with drug that can assist the human antibodies perform their functions better. Clay Siegall founded the research company in the year 1988. The antibodies that Seattle Genetics produces, have the ability that ordinary antibodies do not. The antibodies they manufacture have the ability to deliver a toxic payload to the cancer cells in the body causing them to destroy it from the inside out.
The development of such antibodies could catapult Seattle Genetics to greater heights. With steady growth over the years, the recent research findings could catapult the company to big league category. With a market value of over $10 billion and 900 employees, the company has risen to become one of the largest biotech companies in Washington. It has further grand ambitions of being among the few companies that graduate from a biotech company to a big pharmaceutical company. However, to achieve this dream, they have invested heavily in research and marketing. The additional workforce of 200 employees will help ease the burden of the great tasks they have to accomplish their goal.
One of the achievements of Seattle Genetics is its flagship drug known as Adcetris. The medicine treats Hodgkin lymphoma. Hodgkin lymphoma is a type of cancer that affects the lymph system and can spread if not detected earlier. If the tests that are underway on the drug prove responsive, selling the drug could be a possibility. Clay Siegall, the founder, chairman, and CEO of Seattle Genetics sees a bright future for the company. His ambitions for Seattle Genetics are clear as his desire for the company to move from being a biotech company and focus more on the development of drugs. Clay Siegall has over 20 years’ experience in the study and research of cancer and therapeutic drug development. His in-depth knowledge has helped Seattle Genetics rise to its current position. Apart from being the founder, CEO, and Chairman of Seattle Genetics, he is an author of 67 scientific papers and a holder of 9 patents. He also serves on the three scientific journal editorial boards.